Recent Updates
Recently added Catalysts
OVID Neutral Sentiment

Child Neurology Foundation

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article provides an overview of Ovid Therapeutics, detailing its leadership, scientific strategy, and pipeline programs including OV329 and OV4071. It highlights the company's culture, career opportunities, and investor-related information. The content is structured to inform stakeholders about the company's operations and offerings.
Price reaction · baseline $3.57 (2023-09-22T16:35:00.000Z) · hit during market hours · 15 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
4.1%
average across 4 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
OV101 (gaboxadol)
Phase 3 · Primary Disease or Condition Being Studied: Angelman Syndrome (AS)

Full Press Release Details

• Our Company Our Story Leadership Board of Directors Scientific Advisory Board
• Our Science Our Pipeline Programs OV329 OV4071 & KCC2 Portfolio Program Posters and Publications Our Scientific Strategy Our Collaborations
• Our Patients
• Our Culture & Careers Our Culture Life at Ovid Our Values Open Positions
• Investors News Events & Presentations Stock Information Financials Governance Publications and Posters
• Contact Us
• Program Posters and Publications
• Our Story
• Leadership
• Board of Directors
• Scientific Advisory Board
• Our Pipeline
• Programs OV329 OV4071 & KCC2 Portfolio
• Program Posters and Publications
• Our Scientific Strategy
• Our Collaborations
• OV329
• OV4071 & KCC2 Portfolio
• Our Culture
• Life at Ovid
• Our Values
• Open Positions
• News
• Events & Presentations
• Stock Information
• Financials
• Governance
• Publications and Posters
ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid OV329 OV4071 neurology biopharma
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$170M liquidity · $6M/mo burn
~27 mo
Minimal dilution risk
Lead asset
OV101 (gaboxadol)Phase 3
Primary Disease or Condition Being Studied: Angelman Syndrome (AS) →

Catalyst track record

+104%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →